Other single-arm trials evaluating anti-PD-(L)1 antibodies as monotherapy or in combination with anti-CTLA4 antibodies have reported similar long-term disease control for patients with advanced dMMR/MSI-H colorectal cancer (14–18). Here, CD274 is linked to colorectal cancer.